-+ 0.00%
-+ 0.00%
-+ 0.00%

Boan Biotech announced that phase III clinical trials of the company's PD-1 inhibitor BA1104 have been completed and reached the main end point, and the company will soon submit a marketing license application for this product to the China National Drug Administration. BA1104 is the first Odivo biosimilar in China to complete phase III clinical trials. The phase III clinical trial was a randomized, double-blind, multicenter clinical study comparing the efficacy and safety of BA1104 and Odivo in the treatment of advanced or metastatic esophageal squamous cell carcinoma patients, respectively. The results showed that the confidence interval between the objective remission ratio between the two fell completely within the preset equivalent limit, proving equivalence.

Zhitongcaijing·11/17/2026 04:17:03
Listen to the news
Boan Biotech announced that phase III clinical trials of the company's PD-1 inhibitor BA1104 have been completed and reached the main end point, and the company will soon submit a marketing license application for this product to the China National Drug Administration. BA1104 is the first Odivo biosimilar in China to complete phase III clinical trials. The phase III clinical trial was a randomized, double-blind, multicenter clinical study comparing the efficacy and safety of BA1104 and Odivo in the treatment of advanced or metastatic esophageal squamous cell carcinoma patients, respectively. The results showed that the confidence interval between the objective remission ratio between the two fell completely within the preset equivalent limit, proving equivalence.